Trial Profile
Safety and pharmacokinetics of ruxolitinib in healthy subjects: A randomized, four-way crossover, double-blind study
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 09 Feb 2018
Price :
$35
*
At a glance
- Drugs Ruxolitinib (Primary)
- Indications Myelofibrosis
- Focus Adverse reactions
- 09 Feb 2018 New trial record